BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Comment by webpiloton May 03, 2011 1:28pm

312 Views

Post# 18523512

RE: quebec holdings got 4 million$ worh at 12.5 c

Undoubtedly Quebec2 entered into this agreement with the company in order to take huge tax write offs. The write offs that they receive will far outstrip the small amount of money that they will receive for the shares.The people involved have other large businesses.

Bullboard Posts

These cold weather stocks are looking to heat up for winter